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1Abstract
The study of brain networks, including derived from functional neuroimaging data, at-
tracts broad interest and represents a rapidly growing interdisciplinary field. Comparing
networks of healthy volunteers with those of patients can potentially offer new, quantitative
diagnostic methods, and a framework for better understanding brain and mind disorders. We
explore resting state fMRI data through network measures, and demonstrate that not only is
there a distinctive network architecture in the healthy brain that is disrupted in schizophre-
nia, but also that both networks respond to medication. We construct networks representing
15 healthy individuals and 12 schizophrenia patients (males and females), all of whom are
administered three drug treatments: (i) a placebo; and two antipsychotic medications (ii)
aripiprazole and; (iii) sulpiride. We first reproduce the established finding that brain net-
works of schizophrenia patients exhibit increased efficiency and reduced clustering compared
to controls. Our data then reveals that the antipsychotic medications mitigate this effect,
shifting the metrics towards those observed in healthy volunteers, with a marked difference
in efficacy between the two drugs. Additionally, we find that aripiprazole considerably alters
the network statistics of healthy controls. Using a test of cognitive ability, we establish that
aripiprazole also adversely affects their performance. This provides evidence that changes to
macroscopic brain network architecture result in measurable behavioural differences. This
is the first time different medications have been assessed in this way. Our results lay the
groundwork for an objective methodology with which to calculate and compare the efficacy
of different treatments of mind and brain disorders.
Introduction
In recent years neuroimaging data and graph theory have allowed for the description of the
topological properties of large-scale brain networks (Bullmore and Ve´rtes, 2013; Bullmore and
Sporns, 2009; van den Heuvel and Hulshoff Pol, 2010). Disorders of the brain have long been
thought to be due to abnormal connectivity patterns, and these networks allow for a quanti-
tative measure of this disruption (Bullmore and Sporns, 2012; Rubinov and Bullmore, 2013).
Schizophrenia is a debilitating psychiatric condition with a range of symptoms including auditory
and visual hallucinations, delusions, disorganised thinking, and cognitive impairment. Various
network-based studies have associated schizophrenia with a subtle randomisation of connections
(Alexander-Bloch et al., 2013; Fornito, 2012; van den Heuvel et al., 2013; Lynall et al., 2010;
Rubinov and Bullmore, 2013; Yu et al., 2011). Antipsychotic medications are employed to treat
symptoms with varying degrees of success and side-effect. Sulpiride is a selective dopamine an-
tagonist most commonly used in Europe and Japan for schizophrenia treatment. Aripiprazole is
an atypical third generation antipsychotic introduced for the treatment of schizophrenia in the
USA in 2002 and Europe in 2004 (Bolstad et al., 2015). It acts as a dopamine receptor partial
agonist, whereas typical antipsychotics used to combat the symptoms of schizophrenia are pure
dopamine antagonists. Partial agonists have long been of interest (Lieberman, 2004) in order to
avoid the extrapyramidal and endocrine side effects caused by typical antipsychotics.
To date, very few studies have been conducted to understand if and how medication alters
an individual’s brain network (Achard and Bullmore, 2007; Flanagan, 2018; Hadley et al., 2016).
We hypothesised that an effective medication would act to make the functional brain networks
of patients more similar to those of healthy volunteers. We set out to test this in the context of
three drug treatments: (i) placebo; (ii) aripiprazole, and (iii) sulpiride. We used resting state
2fMRI data to analyse the functional connectivity, and a working memory task to assess the
cognitive abilities, of 15 healthy volunteers and 12 patients with chronic schizophrenia.
Our results show that schizophrenia patients and healthy controls exhibit different network
topologies, in agreement with the existing literature (Alexander-Bloch et al., 2013; Lynall et al.,
2010). Further, the drug treatments alter the topology of the brain network in a measurable
way, both in healthy individuals and patients. In the brain networks of patients we found
evidence that the drugs lead to network topologies that are closer to those of healthy individuals.
This correlates with improved cognitive performance. In healthy individuals, treatment with
aripiprazole leads to a significantly altered network as well as lower cognitive performance.
3Materials and Methods
Experimental Design and Statistical Analysis
Sample
Twelve people with chronic schizophrenia and 15 healthy, nonpsychotic volunteers were recruited
for participation in this study. The patients were diagnosed according to standard operational
criteria in the DSM-IV (American Psychiatric Association, 2000) and were clinically stable
during their involvement (i.e. exhibiting low symptom ratings and undergoing no change of
medication in the preceding four weeks). All were receiving antipsychotic drugs, and four were
receiving additional psychotropic medication, but were not treated with their usual medication
on the days of scanning to avoid effects on the fMRI data. Healthy volunteers were selected to
match the patient group in terms of age, gender, premorbid IQ, years of education and handed-
ness, and screened for major psychiatric disorders using the Mini International Neuropsychiatric
Interview (Sheehan et al., 1998). All subjects provided informed consent in writing and the pro-
tocol was approved by the Addenbrooke’s NHS Trust Local Research Ethics Committee.
Every subject attended three scanning sessions, each one to two weeks apart, for collection
of functional MRI data and completion of working memory tests (see below). At each visit they
were administered one of three drug treatments: (i) an oral placebo 180 and 90 mins before
scanning; (ii) oral aripiprazole 15mg 180 mins before scanning and oral placebo 90 mins before;
(iii) oral placebo 180 mins before scanning and oral sulpiride 400 mg 90 mins before. We used
a double dummy design with dosing of aripiprazole 180 mins and sulpiride 90 mins before the
start of fMRI scanning. At both time points (-180 mins and -90 mins) we co-administered
10mg of Domperidone to minimise side effects (nausea). Both aripiprazole and sulpiride are
antipsychotic medications designed to alleviate the symptoms of schizophrenia. The order of
drug administration and the playlists of the working memory paradigm were counterbalanced
across one group and repeated for the other.
Working memory tests
At each session, the subjects were required to complete an “N-back” task to assess their verbal
working memory (Baddeley, 2003; Koshino, 2005). The task demanded that subjects maintain
a series of visually presented letters in their working memory such that each stimulus could be
compared to the letter presented N letters earlier in the series (i.e. N-back) - see Figure 2(a). For
example, if the sequence of letters was F-B-A-C, the subject could be expected to indicate on
presentation of the last letter in the series that B was presented two letters previously (2-back).
Difficulty was manipulated to 4 levels (0-back to 3-back) by varying the number of letters back
in the series that the subject had to compare to the current letter. All subjects completed a
practice version and three playlists matched for difficulty and distraction, which were allocated
across sessions such that each subject would complete each playlist once across their three visits
(for placebo, aripiprazole, and sulpiride). An individual’s performance at this cognitive task
was assessed by recording their hit rate, defined as the proportion of times they were able to
successfully present a correct answer. In each session, there were 10 correct targets for each N-
back level. Data for the performance of patients 11 and 12 administered sulpiride were missing
4so analyses were carried out without them.
Acquisition and preprocessing of fMRI data
A General Electric (GE) Signa system scanner operating at 1.5 T at the BUPA Lea Hospital
(Cambridge, UK)) was used to acquire functional MRI data over 17 min 12s, during which
time subjects were asked to lie quietly with their eyes closed. In each session, 516 gradient-echo
T2*-weighted echo planar images depicting blood oxygenation level-dependent (BOLD) contrast
were generated from 16 noncontiguous near-axial planes: repetition time = 2 s, echo time = 40
ms, flip angle = 70 ◦, voxel size = 3.05 × 3.05 × 7.00 mm, section skip = 0.7 mm, matrix size
= 64 × 64, field of view (FOV) = 240 × 240 × 123 mm. 4 volumes were discarded to allow for
T1 equilibration effects, leaving 512 volumes per dataset (Lynall et al., 2010).
Control 2 was missing an anatomical image so was discarded from the study, and patient
11 was missing data for the aripiprazole treatment. Each dataset was analysed for effects of
head motion within the scanner (Power et al., 2012; Satterthwaite et al., 2012; Van Dijk et al.,
2012), resulting in the further rejection of patient 3 on aripiprazole and sulpiride, control 10 on
placebo and sulpiride, control 8 on sulpiride, and patient 5 on placebo, all of which were deemed
to have too many motion related artefacts to be reliable. The remaining datasets were corrected
for motion through realignment and wavelet despiking (Patel et el, 2014; Suckling et al., 2006).
We used a 12 parameter affine transformation to register the data to MNI stereotactic standard
space and a 6mm Gaussian kernal for spatial smoothing. Finally, the voxel timeseries were high-
and low-pass filtered with cutoff frequencies of ≈ 0.01 Hz and ≈ 0.08 Hz respectively.
Kolmogorov-Smirnov test
The two-sample Kolmogorov-Smirnov test is a non-parametric test to compare two sets of data.
The Kolmogorov-Smirnov statistic is a measure of the distance between the empirical distribu-
tion functions of the two samples and is calculated under the null hypothesis that both samples
are taken from the same continuous probability distribution. The statistic can then be used to
assign a p-value to the likelihood that the null hypothesis may be rejected. We used this method
to assess the distribution of the global network measures for each of the 6 groups: controls (×3
- aripiprazole, placebo, sulpiride) and patients (×3 - aripiprazole, placebo, sulpiride). A p-value
of < 0.05 was taken to indicate a significant result.
Analysis of variance (ANOVA)
To examine the effects of the drugs, volunteer type and task difficulty on cognitive performance,
we performed a 3 way ANOVA with 2 repeated measures (Cohen, 2007) in various combinations
on the hit rates of the subjects. A p-value of < 0.05 was taken to indicate a significant result.
Anatomical parcellation and wavelet decomposition
For each individual dataset, voxel time series were averaged within each of the 325 equally sized
anatomical regions in a random driven atlas (see (Zalesky et al., 2010) for approach). 28 regions
lacked good quality fMRI timeseries for some subjects so were discarded from our analysis,
5leaving datasets for 297 brain regions for all subjects. The maximal overlap discrete wavelet
transform (Percival and Walden, 2000) was used to decompose each individual regional mean
fMRI time series into the frequency interval 0.030 - 0.060 Hz (scale 3). This frequency range
was selected as it is has been shown that frequencies of ≤ 0.1 Hz exhibit the most prominent
salient neuronal fMRI dynamics (Achard et al., 2006).
Topological network construction
Undirected weighted networks were generated for each individual based on correlating scale
3 wavelet coefficients. The resulting correlation coefficients rij form the weight of the edges
connecting regions i and j. A simple thresholding procedure was then applied to eliminate
edges with weights smaller than τ ; all remaining edges are then given a weight of 1, providing
an undirected, unweighted network. The threshold τ can be varied to generate networks with any
desired percentage of possible connections. Following the example of (Lynall et al., 2010), which
studies a subset of this particular dataset, we choose to focus on 37%−50% connectivity. Firstly,
this ensures that all graphs are connected, and secondly, it avoids the increasing randomness
associated with higher connection densities (Humphries et al., 2006). All results given for the
unweighted networks are averages across this range.
Global network measures
Clustering
The clustering coefficient, Ci, for a node i can be defined as (Watts and Strogatz, 1998):
Ci =
2T (i)
ki(ki − 1) (1)
where T (i) is the number of triangles containing node i, and ki is the degree of i - see Figure
1(a).
The average clustering then provides a global network measure of clustering, and is simply
the average of all values of nodal clustering, or:
C =
1
N
∑
i∈G
Ci (2)
Characteristic path length
If the shortest path lengths, Lij , between all existing node pairs i and j, are identified, then the
characteristic path length of the network, L, is simply given by the mean of their sum:
L =
1
N(N − 1)
∑
i 6=j∈G
Lij (3)
6Efficiency
A measure of the global efficiency of a network, EGlobal, is given by the mean of the sum of the
inverse shortest path lengths, Lij , between all existing node pairs i and j (Achard and Bullmore,
2007; Latora and Marchiori, 2001):
EGlobal =
1
N(N − 1)
∑
i 6=j∈G
1
Lij
(4)
where N is the number of nodes in the graph G. Networks for which the average path length
is small can thus be said to have high global efficiency (Achard and Bullmore, 2007) (see Figure
1(a)).
This is equivalent to averaging the nodal efficiencies for all nodes in the network.
Assortativity
The assortativity of a network is a measure of the preference of its nodes to connect to other
nodes of similar degree. Let exy be the joint probability distribution (or mixing matrix) of the
degrees. Then if
∑
y exy = ax and
∑
x exy = by are, respectively, the fraction of edges that start
and end at vertices with values x and y and further that exy 6= axby (the case of no assortative
mixing), the assortativity coefficient can be defined simply by calculating the Pearson correlation
coefficient (Newman, 2003):
A =
∑
xy xy(exy − axby)
σaσb
(5)
where σa and σb are the standard deviations of the distributions ax and by. A has a value
in the range −1 ≤ r ≤ 1, where A = 1 would correspond to a perfect correlation between x and
y, ie perfect assortativity, and similarly A = −1 would indicate perfect disassortativity.
Software
Motion diagnostics, preprocessing and parcellation of the functional MRI data were completed
using the preprocessing pipeline with temporal despiking from (Kundu et al., 2012; Patel et el,
2014). Metric calculations and network manipulations were carried out using the Python net-
workx library (Hagberg et al., 2008) and Matlab. We used IBM SPSS Statistics for all ANOVA
calculations (IBM Corp., 2012).
7Results
The effects of schizophrenia on global efficiency and clustering are mitigated
by medication
We first compared the functional brain networks derived from schizophrenia patients and healthy
volunteers on placebo treatments, and as expected, (Alexander-Bloch et al., 2013; Lynall et al.,
2010) find distinct differences. In agreement with the existing literature, the schizophrenia
networks have increased efficiency (average EGlobal,SZ = 0.714 compared to EGlobal,HV = 0.712,
p = 0.04) and reduced clustering (average CSZ = 0.674 compared to CHV = 0.707, p = 0.01) -
see Figure 1.
We next employed an ANOVA (two-way, one repeated measure) to examine any differences
in network measures between groups, and the factors underlying them. This confirmed group
differences due to subject type on both efficiency and clustering (p = 0.010 and p = 0.002
respectively), and also indicated group differences due to drug effect (p = 0.041 and p = 0.05
respectively) - see Tables 1 and 2. Our hypothesis was that the antipsychotic medications would
aim to make the brain connectivities of patients more similar to those of healthy individuals.
In the light of the observed differences between the control and patient placebo groups, this
hypothesis translates to an expectation that aripiprazole and sulpiride will reduce efficiency and
increase clustering. We do indeed find this, both for patients and for healthy volunteers (Figure
1), with the only exception of when patients were treated with sulpiride, for which there was
no effect on global efficiency. Moreover, after each drug treatment the brain networks of people
with schizophrenia had global efficiencies which were no longer statistically different from the
healthy brain networks (average EGlobal = 0.713, p = 0.241 for aripiprazole and EGlobal = 0.715,
p = 0.081 for sulpiride). Both drugs also led to average clustering coefficients that were much
closer to those of healthy brain networks (average C = 0.681, p = 0.032 for aripiprazole, C =
0.677, p = 0.081 for sulpiride).
Aripiprazole significantly changes healthy brain networks
We found that aripiprazole has a dramatic effect on healthy individuals, with a large variation
across individuals. We observe significantly reduced global efficiencies (average EGlobal = 0.704,
σ = 0.009, p = 0.006), and a considerable increase in clustering (C = 0.743, p<0.001). Sulpiride
increased clustering in healthy networks (average C = 0.726, p = 0.028), but had no significant
effect on global efficiency (average EGlobal = 0.709, p = 0.321). Almost all metrics examined
are greatly altered in the healthy volunteers administered aripiprazole, indicating considerable
restructuring of functional connectivity: see Figure 1). These results are consistent with obser-
vations in the brain networks of people with schizophrenia: the drug treatments reduce efficiency
and increase clustering.
Cognitive performance of healthy individuals is impaired after taking arip-
iprazole
All subjects score consistently highly on the very easy 0-back task, but their performance dete-
riorates considerably with increasing difficulty of the task, with subjects experiencing profound
8Figure 1. Average clustering and global efficiency values. The box plots display
distributions of (a) average clustering and (b) global efficiency for the networks of each group
and drug. Schizophrenia is associated with lower clustering and higher efficiency. The
antipsychotic medications increase clustering and decrease efficiency, therefore moving patients
closer to controls and affecting the control networks. The schematics illustrate the concepts of
(a) clustering and (b) efficiency. (a) Clustering measures the number of triangles which exist
around around a node (green solid lines), as a proportion of those that could (also green
dashed lines). (b) Efficiency averages the inverse shortest paths (green lines) between all node
pairs; many short paths equates to higher efficiencies.
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Figure 2. N-back working memory task. Panel (a) illustrates the nature of the task.
Subjects are shown a sequence of letters, and asked to recall the letter which is “N-back”. In
the example shown, the correct answer to the 1-back version is A, to the 2-back version B, etc.
For each drug treatment, hit rates from (b) healthy individuals and (c) schizophrenia patients
averaged across each level of difficulty are presented. Values below the boxes represent the
median values, and for the drug treatment groups, the difference with the median of the
placebo group is provided in brackets. Aripiprazole is associated with a reduced number of
correct answers as compared to placebo.
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Source SS df MS F p
Between groups
Subject type 0.026 1 0.026 12.208 0.002
Error 0.040 19 0.002
Within groups
Drug 0.004 2 0.002 6.023 0.005
Drug*Subject type 0.004 2 0.002 5.997 0.005
Error 0.012 38 < 0.001
Table 1. Summary statistics for a 2 way ANOVA with 1 repeated measure on the
network global clustering values of patients and healthy controls treated with
placebo, aripiprazole, and sulpiride. Individuals for which networks were available for all
drug treatments were used. There is a significant difference between the network clustering of
the HV and SZ groups (p = 0.002), a significant drug effect (p = 0.005) and an additional
drug-group type interaction term (p = 0.005) - all highlighted in red. This interaction term
stems from the effect of aripiprazole - it greatly increases the clustering of control networks
whilst causing only a small and variable increase in the schizophrenia networks. The placebo
and sulpiride treatments have a more consistent effect on the two groups.
difficulty with the 3-back version (see Figure 2). In the healthy cohort, aripiprazole has a detri-
mental effect on performance, whereas the impact of sulpiride is negligible - see Figure 2(b). In
the challenging 2-back version of the task, the disparity is most clear - aripiprazole has a negative
impact on cognitive performance, giving rise to an average hit rate of 0.65± 0.21 (compared to
0.83 ± 0.19 on placebo). Sulpiride, however, has no noticeable impact, with subjects achieving
an average hit rate of 0.83± 0.18.
An ANOVA (three-way, two repeated measures) revealed that, naturally, the predomi-
nant factor in determining success at the working memory tests was the difficulty of the task
(p<0.0001) - see Table 3. However, it also demonstrated that the drug treatments have a signif-
icant effect (p = 0.007). We then separated out the drug treatments into placebo-aripiprazole
and placebo-sulpiride groups and repeated the ANOVA on controls and patients separately.
This shows that the effect is only observed in the healthy volunteers, and that aripiprazole is
the medication responsible (p = 0.015 for the placebo-aripiprazole groups and p = 0.769 for the
placebo-sulpiride groups). Thus, amongst healthy volunteers, we find that aripiprazole results
in poorer performance at the N-back working memory task as compared to placebo, and that
sulpiride has no noticeable effect.
Cognitive tests show worse performance of patients but do not capture drug
effects
Patients scored worse than controls in the N-back working memory task, but not significantly
so, with an average hit rate of 0.73±0.18 for patients and 0.83±0.19 for controls for the placebo
2-back task. Aripiprazole and sulpiride do not change the performance of patients much (average
hit rates of 0.71±0.21 and 0.79±0.28 respectively for the 2-back task) with an ANOVA showing
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Source SS df MS F p
Between groups
Subject type < 0.001 1 < 0.001 8.093 0.010
Error 0.001 19 < 0.001
Within groups
Drug < 0.001 2 < 0.001 3.480 0.041
Drug*Subject type < 0.001 2 0.0001 1.005 0.376
Error 0.0010 38 < 0.001
Table 2. Summary statistics for a 2 way ANOVA with 1 repeated measure on the
network global efficiency values of patients and healthy controls treated with
placebo, aripiprazole, and sulpiride. Individuals for which networks were available for all
drug treatments were used. There is a significant difference between the network efficiency of
the HV and SZ groups (p = 0.010) and a significant drug effect (p = 0.041) - highlighted in red.
no significant drug effect (p = 0.217) - see 2(c).
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Source SS df MS F p
Between groups
Subject type 0.007 1 0.007 0.044 0.836
Error 3.762 23 0.164
Within groups
Drug 0.386 2 0.193 5.489 0.007
Drug*Subject type 0.011 2 0.006 0.160 0.853
Error 1.618 46 0.035
Cog. difficulty 4.828 3 1.609 42.779 <0.0001
Cog. difficulty*Subject type 0.045 3 0.015 0.403 0.751
Error 2.596 69 0.038
Drug*Cog. difficulty 0.120 6 0.020 1.160 0.331
Subject type*Drug*Cog. difficulty 0.162 6 0.027 1.160 0.331
Error 2.384 138 0.017
Table 3. Summary statistics for a 3 way ANOVA with 2 repeated measures on the
hit rates during a working memory task with 4 levels of difficulty of patients and
healthy controls treated with placebo, aripiprazole, and sulpiride. Individuals for
which data were available for all drug treatments were used. We see a significant effect of
cognitive difficulty (p < 0.001) and a significant drug effect (p = 0.007) - highlighted in red.
Discussion
Network topology, illness, and medication
It has been known for some time that the functional brain network organisation of people with
schizophrenia differs from that of healthy volunteers (Alexander-Bloch et al., 2013; Lynall et al.,
2010). However, very few studies have been conducted into the effect of antipsychotic medication,
or indeed any drug for any brain disorder, on this network organisation. The ones that have
been conducted found measurable drug effects (Achard and Bullmore, 2007; Flanagan, 2018;
Schmidt et el., 2013; Yang et al., 2014) (including, converse to treatment, inducing psychosis
(Lahti et al., 2001)). We hypothesised that a drug designed to treat schizophrenia would modify
the brain connectivities of patients, making them more similar to those of healthy individuals.
The result for global efficiency and clustering in Figure 1 clearly demonstrate this principle -
sulpiride and aripiprazole act to reduce efficiency in both controls and patients. This leaves
the patients with network efficiencies and clustering comparable to those of the unmedicated
controls, and the controls with lower efficiency and higher clustering than before. In addition
we also observed a strong effect of aripiprazole on healthy controls (see Figure 1 and Tables
1 and 2. This finding is consistent with our result in patients, as the drug seemingly tries to
‘correct’ for schizophrenia network characteristics - in the absence of schizophrenia - by altering
13
the network metrics to decrease efficiency and increase clustering..
Network topology and cognitive ability
Our results suggest that there is an optimal configuration for a brain network in terms of
maximising cognitive ability: performance worsens given any change (increase or decrease) in
the examined metrics. We saw that as well as having a characteristically different brain network
structure, schizophrenia patients perform less well at tests of cognitive ability than their healthy
counterparts, as has been previously demonstrated (Bullmore and Sporns, 2012). Further, we
showed that the group who performed most differently on medication (healthy volunteers having
been administered aripiprazole) was also the group who had the most changes to the topology
of their brain networks. This supports the notion that one’s cognitive ability is intrinsically
linked to the structure of the brain’s functional network (Basset et al., 2009). For example,
to integrate and process information quickly, a network requires some level of efficiency. The
control group on aripiprazole had diminished efficiency and performed significantly worse at the
N-back tasks than when on placebo. No such impaired performance is seen for sulpiride, for
which the reduction in efficiency was negligible. On the other hand, the schizophrenia brain
networks appear to have too high an efficiency, perhaps leading to disordered or overwhelming
information integration, and they too perform worse. The drugs do decrease efficiency in patients
a little and their performance is slightly improved at the 1- and 2-back tasks. A previous study
on MEG derived networks using the N-back working memory paradigm (Kitzbichler et al.,
2011) demonstrated a shift towards a more random network configuration (with a decrease in
modularity and clustering, and an increase in global efficiency) as the cognitive demands of
the task increased. The authors also note significant differences from purely random networks
and argue that global sychronisation is important in higher cognition, which is reflected in the
network architecture.
Brain networks as a means to assess medication
This quite unique dataset allowed for an investigation into the effects of antipsychotic drugs on
both the large-scale functional brain networks and the cognitive performance of people diagnosed
with chronic schizophrenia and healthy volunteers. Despite its limitations, clear drug effects were
observed on the network topology and performance at the N-back working memory task. We find
a restoration of the healthy network properties in the patient networks, and that aripiprazole
impairs cognitive ability and radically rewires the brain networks of healthy volunteers. It
would be highly beneficial for future studies to use state of the art functional MRI data to
further investigate the links between disrupted networks in people with brain disorders, how
medication influences these, and an “ideal” network topology for the brain (which should be
identified by association with an optimal behavioural parameter, such as the best cognitive
performance). There is potential for not just diagnosis of the original brain disorder, but also
for the quantification of the effectiveness of a drug in treating the illness, and even guidance
on its optimal dosage. This would then allow for a systematic comparison between alternative
treatments.
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